Advertisement
CRL's ultra-fast library production process is optimized at every step andincludes: on-the-fly building block validation and protocol adjustment; one tothree parallel synthesis steps across a very broad reaction range;high-throughput HPLC purification and LC/MS analysis; data processing; androbotic reformatting to ready-to-be-shipped custom plates/vials. Theexpertise, problem solving ability, and versatility of synthetic skills ofCRL's chemists (the majority of whom are PhD's) also allow for rapiddevelopment of new parallel synthetic protocols and multi-step synthesis ofintermediates and templates on-the-fly for the most challengingresearch-intensive hit-to-lead libraries.
Advertisement
"We are very pleased that our CRL chemists have been able to achieve speedand efficiency in hit-to-lead library production which even a year ago was notconsidered possible," said Eugene Vaisberg, Chairman and CEO of ChemBridgeCorporation and CRL. "Their ability to produce and deliver high qualityhit-to-lead libraries in less than a week continues the ChemBridge traditionof setting a gold standard in discovery chemistry outsourcing. It also offersa substantial competitive advantage for our clients allowing their preciousmedicinal chemistry resources to focus on their core expertise and to improvetheir hit-to-drug candidate success rate and timelines. This is of foremostimportance now when research efficiency and productivity becomes the 'name ofthe game' for the pharmaceutical and biotech industry."
About ChemBridge Research Laboratories, Inc. (CRL)
ChemBridge Research Laboratories, Inc. (CRL),http://www.chembridgeresearch.com, is a San Diego based discovery chemistryCRO, which provides chemistry solutions for early stages of small moleculedrug discovery. Founded in 2000 as a spin-off of ChemBridge Corporation, CRLhas now become a center of excellence in high-throughput medicinal chemistrywith a particular focus on ultra-fast hit-to-lead libraries. CRL's world-classresearch team has exceeded expectations in all its collaborations, includingmulti-year alliances with Pfizer, Merck, AstraZeneca and other majorpharmaceutical and biotech companies.
About ChemBridge Corporation
ChemBridge Corporation, http://www.chembridge.com, is a leading globaldiscovery chemistry CRO and screening compound library provider with animpeccable 15 year track record of quality and deliverability. ChemBridge is aSan Diego based company which operates a state-of-the-art offshore discoverychemistry research site in Moscow, Russia. ChemBridge's CRO business includesmulti-year strategic alliances with major pharmaceutical companies such asPfizer, Merck, and AstraZeneca, as well as smaller research collaborationswith mid-size pharmaceutical and biotech companies. Over 500 pharmaceuticaland biotech companies and universities worldwide have also taken advantage ofChemBridge's portfolio of advanced discovery chemistry off-the-self products,including its library of 700,000 diverse drug-like small molecule screeningcompounds and 10,000 building blocks.
SOURCE ChemBridge Research Laboratories, Inc.
